290 related articles for article (PubMed ID: 27168137)
1. The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Chow BS; Koulis C; Krishnaswamy P; Steckelings UM; Unger T; Cooper ME; Jandeleit-Dahm KA; Allen TJ
Diabetologia; 2016 Aug; 59(8):1778-90. PubMed ID: 27168137
[TBL] [Abstract][Full Text] [Related]
2. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
[TBL] [Abstract][Full Text] [Related]
3. Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo.
Sampson AK; Irvine JC; Shihata WA; Dragoljevic D; Lumsden N; Huet O; Barnes T; Unger T; Steckelings UM; Jennings GL; Widdop RE; Chin-Dusting JP
Br J Pharmacol; 2016 Feb; 173(4):729-40. PubMed ID: 25560767
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice.
Schwengel K; Namsolleck P; Lucht K; Clausen BH; Lambertsen KL; Valero-Esquitino V; Thöne-Reineke C; Müller S; Widdop RE; Denton KM; Horiuchi M; Iwai M; Boato F; Dahlöf B; Hallberg A; Unger T; Steckelings UM
J Mol Med (Berl); 2016 Aug; 94(8):957-66. PubMed ID: 26983606
[TBL] [Abstract][Full Text] [Related]
5. Activation of angiotensin type 2 (AT2) receptors prevents myocardial hypertrophy in Zucker diabetic fatty rats.
Castoldi G; di Gioia CRT; Roma F; Carletti R; Manzoni G; Stella A; Zerbini G; Perseghin G
Acta Diabetol; 2019 Jan; 56(1):97-104. PubMed ID: 30187136
[TBL] [Abstract][Full Text] [Related]
6. Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
Castoldi G; di Gioia CR; Bombardi C; Maestroni S; Carletti R; Steckelings UM; Dahlöf B; Unger T; Zerbini G; Stella A
Am J Physiol Renal Physiol; 2014 Nov; 307(10):F1123-31. PubMed ID: 25186297
[TBL] [Abstract][Full Text] [Related]
7. C21 preserves endothelial function in the thoracic aorta from DIO mice: role for AT2, Mas and B2 receptors.
González-Blázquez R; Alcalá M; Fernández-Alfonso MS; Steckelings UM; Lorenzo MP; Viana M; Boisvert WA; Unger T; Gil-Ortega M; Somoza B
Clin Sci (Lond); 2021 May; 135(9):1145-1163. PubMed ID: 33899912
[TBL] [Abstract][Full Text] [Related]
8. Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Jing F; Ohshima K; Wang XL; Nakaoka H; Kan-no H; Chisaka T; Bai HY; Min LJ; Horiuchi M
Eur J Pharmacol; 2014 Feb; 724():9-15. PubMed ID: 24361310
[TBL] [Abstract][Full Text] [Related]
9. Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism.
Verdonk K; Durik M; Abd-Alla N; Batenburg WW; van den Bogaerdt AJ; van Veghel R; Roks AJ; Danser AH; van Esch JH
Hypertension; 2012 Sep; 60(3):722-9. PubMed ID: 22802221
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.
Rehman A; Leibowitz A; Yamamoto N; Rautureau Y; Paradis P; Schiffrin EL
Hypertension; 2012 Feb; 59(2):291-9. PubMed ID: 22184324
[TBL] [Abstract][Full Text] [Related]
11. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.
Koïtka A; Cao Z; Koh P; Watson AM; Sourris KC; Loufrani L; Soro-Paavonen A; Walther T; Woollard KJ; Jandeleit-Dahm KA; Cooper ME; Allen TJ
Diabetologia; 2010 Mar; 53(3):584-92. PubMed ID: 19957160
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Chen J; Li D; Schaefer R; Mehta JL
Atherosclerosis; 2006 Feb; 184(2):295-301. PubMed ID: 16005008
[TBL] [Abstract][Full Text] [Related]
14. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.
Joseph JP; Mecca AP; Regenhardt RW; Bennion DM; Rodríguez V; Desland F; Patel NA; Pioquinto DJ; Unger T; Katovich MJ; Steckelings UM; Sumners C
Neuropharmacology; 2014 Jun; 81():134-41. PubMed ID: 24508710
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of angiotensin II type 2 receptor stimulation in vincristine-induced mechanical allodynia.
Bessaguet F; Danigo A; Bouchenaki H; Duchesne M; Magy L; Richard L; Sturtz F; Desmoulière A; Demiot C
Pain; 2018 Dec; 159(12):2538-2546. PubMed ID: 30086116
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice.
Quiroga DT; Muñoz MC; Gil C; Pffeifer M; Toblli JE; Steckelings UM; Giani JF; Dominici FP
Physiol Rep; 2018 Aug; 6(16):e13824. PubMed ID: 30156060
[TBL] [Abstract][Full Text] [Related]
17. Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failure.
Bernardi S; Candido R; Toffoli B; Carretta R; Fabris B
Nephrol Dial Transplant; 2011 Mar; 26(3):832-8. PubMed ID: 20810455
[TBL] [Abstract][Full Text] [Related]
18. Candesartan prevents resiniferatoxin-induced sensory small-fiber neuropathy in mice by promoting angiotensin II-mediated AT2 receptor stimulation.
Bessaguet F; Danigo A; Magy L; Sturtz F; Desmoulière A; Demiot C
Neuropharmacology; 2017 Nov; 126():142-150. PubMed ID: 28882562
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice.
Tiyerili V; Mueller CF; Becher UM; Czech T; van Eickels M; Daiber A; Nickenig G; Wassmann S
J Mol Cell Cardiol; 2012 Mar; 52(3):630-7. PubMed ID: 22230040
[TBL] [Abstract][Full Text] [Related]
20. AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
Chow BSM; Kocan M; Shen M; Wang Y; Han L; Chew JY; Wang C; Bosnyak S; Mirabito-Colafella KM; Barsha G; Wigg B; Johnstone EKM; Hossain MA; Pfleger KDG; Denton KM; Widdop RE; Summers RJ; Bathgate RAD; Hewitson TD; Samuel CS
J Am Soc Nephrol; 2019 Nov; 30(11):2191-2207. PubMed ID: 31511361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
